PharmaSens and SiBionics to develop wearable insulin patch pump

Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump.
Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load.
The wearable will leverage PharmaSens' patented platform technologies along with the biosensor capabilities of SiBionics.
Both companies will offer their engineering and development know-how to bring this patch pump to the market.
PharmaSens CEO Marcel Both said: 'This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system.
'SiBionics' proven expertise in sensor technology is a perfect complement to our platform.'
PharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs.
The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity.
The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM.
PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste.
The company is focused on simplifying diabetes management and expanding access to insulin pump therapy.
Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US.
Last year, PharmaSens submitted an application to the US Food and Drug Administration (FDA) for approval of its niia essential insulin patch pump system.
"PharmaSens and SiBionics to develop wearable insulin patch pump" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

32 minutes ago

• Yahoo

Forget chocolate! The world now envies Switzerland's zero interest rates

The world envies Swiss chocolate, army knives, and now . . . interest rates? Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos 3 tiny behaviors that make you the calmest person in the room Swiss National Bank, Switzerland's central bank, moved interest rates to zero this week, a reduction of 25 basis points, and a notable detraction from other central banks around the world, such as the Federal Reserve in the U.S. and the Bank of England in the U.K. In a statement, the Swiss National Bank said that the move was made in relation to declining inflation worries—and that it's expecting the economies to buckle under the volatility created, in part, due to the Trump administration's trade policies. 'With today's easing of monetary policy, the SNB is countering the lower inflationary pressure. The SNB will continue to monitor the situation closely and adjust its monetary policy if necessary, to ensure that inflation remains within the range consistent with price stability over the medium term,' the statement read. 'The global economic outlook for the coming quarters has deteriorated due to the increase in trade tensions. In its baseline scenario, the SNB anticipates that growth in the global economy will weaken over the coming quarters. Inflation in the U.S. is likely to rise over the coming quarters. In Europe, by contrast, a further decrease in inflationary pressure is to be expected.' Meanwhile, in the U.S., the Federal Reserve's latest meeting wrapped up this week with no change in interest rates, despite pressure from the White House and others to lower them. Fed Chair Jerome Powell and other Fed governors have been reluctant to do so, as inflation data still has not gotten close enough to its 2% target, and employment data has remained positive. Across the Atlantic, however, another European country, Norway, also cut rates this week. And some experts think that the Swiss could go even further, instituting negative interest rates at some point this year. 'There are risks that the SNB will go further in the future if inflationary pressures don't start to increase, and the lowest the policy rate could go is -0.75%, the rate it reached in the 2010s,' Swiss National Bank's Chairman Martin Schlegel told CNBC on Thursday. 'But what I can say is that going negative, we would not take this decision lightly.' This post originally appeared at to get the Fast Company newsletter:

Yahoo

2 hours ago

• Yahoo

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and CHICAGO, June 20, 2025 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, highlighting improved glycemic outcomes for individuals with insulin-intensive type 2 diabetes on the MiniMed™ 780G* system under investigational use. Participants in a clinical trial achieved an average 8.6% increase in Time in Range (TIR), reaching 84.9%, well above the ADA goal of 70%, and a HbA1C reduction from 7.7% to 6.9%, meeting ADA targets for diabetes management. Separately, results from the Medtronic LENNY trial were publishedi in The Lancet Diabetes & Endocrinology. This multi-center, randomized controlled, crossover trial evaluated the MiniMed™ 780G system in young children (ages 2-6 years) with type 1 diabetes in a home setting. Results showed those using the MiniMed™ 780G system with SmartGuard™ achieved a 0.6% lower HbA1C and 9.9% higher Time in Range when compared to a baseline therapy of manual mode or hybrid closed loop without autocorrections. Parents and caregivers also reported improved sleep quality and lower fear of hypoglycemia when the system was used in auto mode (with SmartGuard™) compared to manual mode. Benefits of automated insulin delivery (AID) systems for type 2 diabetesWhile the standard of care for type 2 diabetes often includes lifestyle modifications and oral medications, many individuals require intensive insulin therapy to achieve optimal glucose management. The ADA's 2025 Standards of Careii now endorse the use of AID systems for adults with insulin-intensive type 2 diabetes, recognizing their potential to significantly improve clinical outcomes — an important validation of the growing role of diabetes technology in transforming chronic disease management. A 31-site single arm trial evaluated the MiniMed™ 780G system paired with the Simplera Sync™ sensor in a cohort of 236 individuals with type 2 diabetes. Results were promising across all clinical outcome metrics including Time in Range (TIR), Time in Tight Range (TITR), Time Above Range (TAR) compared to the run-in period where hybrid closed loop (auto basal only) or open-loop delivery was used. Time below range (TBR) remained stable. "As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin," said Dr. Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. "Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before."Baselinea Studyb Change (Study - Baseline) P Participants, N 236 232 -- -- Time in AHCL, % -- 92.4 ± 15.7 -- -- A1C, % 7.7 ± 0.9 6.9 ± 0.7c -0.8 ± 0.9c <0.0001 Mean SG, mg/dL 152.9 ± 21.2 140.7 ± 13.3 -12.3 ± 19.5 <0.0001 CV of SG, % 25.1 ± 4.8 25.6 ± 4.8 0.4 ± 3.3 0.073h TBR <54 mg/dL, % 0.0 ± 0.1 0.0 ± 0.1 -0.0 ± 0.1 0.277 TBR <70 mg/dL, % 0.3 ± 0.5 0.3 ± 0.4 0.0 ± 0.5 0.056 TITR 70-140 mg/dL, % 45.3 ± 19.7 58.1 ± 13.6 13.0 ± 18.8 <0.0001h TIR 70-180 mg/dL, % 76.4 ± 15.9 84.9 ± 9.7 8.6 ± 14.4 <0.0001 TAR >180 mg/dL, % 23.4 ± 15.9 14.8 ± 9.7 -8.6 ± 14.5 <0.0001 TAR >250 mg/dL, % 3.5 ± 5.2 1.7 ± 2.5 -1.8 ± 4.6 <0.0001 TDD, U 61.0 ± 36.1 76.1 ± 44.1 14.5 ± 25.1 <0.0001 Basal and bolus insulin Total basal, U 34.6 ± 21.3 39.8 ± 23.9 4.9 ± 16.8 <0.0001 Total bolus, U 26.5 ± 20.7 36.3 ± 23.8 9.6 ± 15.1 <0.0001 Auto bolus, U -- 13.7 ± 11.1 -- -- Auto bolus, %TDD -- 17.2 ± 8.5 -- -- Auto bolus, %Total bolus -- 39.3 ± 21.8d -- -- System-initiated insulin Automated insulin, U 0.5 ± 3.4 51.2 ± 33.4 50.7 ± 33.7 <0.0001 Automated insulin, %TDD 0.9 ± 5.8 65.9 ± 17.3 65.0 ± 17.8 <0.0001 Daily carbohydrate, g 119.1± 87.4 127.7 ± 88.9 7.7 ± 84.6 0.571 ICR 7.6 ± 4.0d 6.9 ± 3.8e -0.6 ± 1.5f <0.0001 Weight, kg 98.0 ± 22.8g 98.4 ± 23.0c 0.7 ± 4.7c 0.006 BMI, kg/m2 34.0 ± 7.3g 34.2 ± 7.4c 0.2 ± 1.7c 0.006 Table 1. Glycemic outcomes, insulin delivery and weight during MiniMed™ 780G system use with the Simplera Sync™ sensor in adults with type 2 diabetes Data are shown as mean± loop (with or without predictive low glucose management) or HCL. AHCL was inadvertently (temporarily) enabled on 13 represent the last 6 weeks of the study period with glucose target set at the investigator's dN=231, eN=228. fN= two-sided t-test; otherwise, Wilcoxon signed-rank Body mass index; CV, Coefficient of variation; ICR, Insulin-to-carb ratio; SG, Sensor glucose; TAR, Time above range; TBR, Time below range; TIR, Time in range; TITR, Time in tight range; TDD, Total daily dose; U, MiniMed™ 780G system has not been approved for use in type 2 diabetes by U.S. FDA or other regulatory bodies. Impact on families of young children with diabetesManaging type 1 diabetes in young children and toddlers can be challenging for families. Data from the Lenny trial, published in The Lancet Diabetes & Endocrinology, highlighted how young children aged 2-6 years old achieved improved glycemic outcomes using the MiniMed™ 780G system. "To preserve brain development and minimize long-term diabetes complications, it is essential that blood glucose concentrations are maintained close to healthy ranges from disease onset in early life," said Prof. Tadej Battelino, MD, Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Slovenia. "We are hopeful that if the data continues to be strong, the MiniMed™ 780G system can help make this possible." After a run-in phase, subjects using the MiniMed™ 780G system with the Guardian™ 4 sensor were randomized into two sequences, consisting of a 12-week auto mode period (advanced hybrid closed loop), a 2-week wash-out phase and 12-week manual mode period (with suspend before low feature activated), or vice-versa. In total, there were 98 subjects across 12 centers in 4 countries. Results showed significantly** better glycemic management in auto mode, as shown in Figure 1 and Table 2 below. With no severe hypoglycemic events, the study showed an acceptable safety profile. Participants in auto mode spent on average 145 minutes per day more in range than those in manual mode. This improvement was primarily driven by a reduction in hyperglycemia, which is a major contributor to long-term complications. "We're hopeful that if the data continues to be strong, we will receive future indication expansion so the most vulnerable group, small children under 7 years, and their families can also benefit from this technology ", said Prof. Ohad Cohen, M.D., senior global medical affairs director, Medtronic Diabetes. Table 2: Glycemic metrics during the run-in phase, the manual mode period, and the auto mode Manual Mode Auto Mode HbA1c, % 7.53 ± 0.96 7.61 ± 0.91 7.00 ± 0.53 HbA1c, mmol/mol 58.8 ± 10.5 59.7 ± 9.9 53.0 ± 5.8 Mean glucose, mg/dl 169.6 ± 25.7 169.1 ± 23.1 150.2 ± 10.7 SD of SG, mg/dl 65.0 ± 14.7 65.4 ± 13.2 61.8 ±10.9 GMI, % 7.4 ± 0.6 7.4 ± 0.5 6.9 ± 0.3 Table 2: Glycemic metrics during the run-in phase, the manual mode period, and the auto mode period. During manual mode, the suspend before low (SBL) feature was activated. During run-in, the system was also used in manual mode with SBL activated. Data are shown as mean ± SD. The emotional toll of diabetes for parents and caregiversManaging type 1 diabetes in toddlers and young children can be emotionally stressful for parents and caregivers due to the need for constant blood sugar monitoring, dietary management, insulin administration and disrupted routines and sleep. A survey of caregivers in the LENNY trial indicated that when their child used auto mode, they experienced relatively low fear of hypoglycemia and high sleep Manual Mode Auto Mode Parent hypoglycemia fear survey (HFS-P) 44.75 ± 14.9 42.9 ± 13.3 40.9 ± 13.2 Pittsburgh Sleep Quality Index (PSQI) 7.1 ± 3.8 7.1 ± 4.0 5.9 ± 3.2 Table 3: Parent hypoglycemia fear survey and Pittsburgh Sleep Quality Index during the run-in phase, the manual mode period and the auto mode period. During manual mode, the suspend before low (SBL) feature was activated. During run-in, the system was also used in manual mode with SBL activated. Medtronic will seek future expansion of indications for a broader populationThe MiniMed™ 780G system currently is not indicated for use in in type 2 diabetes or young children under 7 years old by the U.S. Food and Drug Administration (FDA) or other regulatory bodies. Medtronic intends to work with global regulators towards expanding access to its diabetes technology for insulin-intensive type 2 diabetes, as well as a lower age indication for those with type 1 diabetes. About the Diabetes Business at Medtronic Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. *MiniMed™ 780G system is for type 1 ages 7 years and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. See the User Guide for a detailed list of information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For details, see Significance was shown via confidence intervals§ Refers to SmartGuard™ feature. Individual results may vary.† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off. i Battelino et al. Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial; Lancet Diabetes Endocrinol 2025ii American Diabetes Association Professional Practice Committee: Diabetes Care 2025;48(Supplement_1):S146–S166 Contacts:Ashley Patterson Ryan Weispfenning Global Communications Investor Relations +1-818-576-3025 +1-763-505-4626 View original content to download multimedia: SOURCE Medtronic plc

Business Wire

2 hours ago

• Business Wire

CCS Presents Four Peer-Reviewed Posters at American Diabetes Association's 85th Scientific Sessions

CHICAGO--(BUSINESS WIRE)-- CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association's (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS's focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to thrive and cost-effectively stay adherent while managing their chronic condition. "At CCS, we meet patients where they are — with empathy, education, and evidence-based support..." Share The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, innovation, and new evidence-based approaches to diabetes prevention, management, and care. Presentation Highlights from CCS at the ADA Scientific Sessions CCS's clinical strategy and innovation vice president, Coni Dennis, DNP, RN, and NE-BC, will present findings for all four accepted poster presentations at the ADA's 85th Scientific Sessions, and she shared this insight leading into the event: 'At CCS, we meet patients where they are — with empathy, education, and evidence-based support. These poster presentations reflect our commitment to improving health outcomes for people with diabetes by combining data-driven clinical insight with hands-on, compassionate care.' All poster presentations will take place at the conference on Sunday, June 22, from 12:30–1:30 p.m. CT in West Hall F1. The following are the four specific posters that CCS will be presenting: Presentation Title: Evaluating the Impact of Multichannel Diabetes Care Coaching and Education in Patients New to Continuous Glucose Monitoring Abstract Number: 534 Summary: This study, part of an ongoing randomized control trial (RCT), evaluated whether adults with diabetes newly starting a continuous glucose monitor (CGM) achieve better outcomes when they receive diabetes self-management education and support (DSMES) from a certified diabetes care and education specialist (CDCES), compared to using a CGM alone. Presentation Title: Examining the Impact of Continuous Glucose Monitoring Sourcing in Medicaid Patients — Adherence, Healthcare Costs, and Utilization Abstract Number: 1046 Summary: This study compared healthcare costs and utilization among Medicaid beneficiaries who received CGM supplies through a pharmacy or a durable medical equipment provider. Presentation Title: Healthcare Costs and Utilization Among Patients Eligible for Continuous Glucose Monitors — A Comparison of Users and Nonusers Abstract Number: 1049 Summary: This retrospective cohort study used claims data to compare glycemic control, healthcare utilization, and total cost of care over 12 months among individuals on bolus insulin who used CGMs versus those who did not. It also assessed the incidence of hypoglycemia and diabetic ketoacidosis (DKA). Presentation Title: Evaluating an Evidence-Based Quality Improvement Initiative for Food Insecurity Screening and Referral in Adults with Diabetes Initiating Continuous Glucose Monitor Therapy Abstract Number: 1143 Summary: This study assessed food insecurity (FI) among adults with diabetes initiating CGM therapy, comparing rates to national averages and examining glycemic outcomes between food-insecure and food-secure individuals. These posters will be made available on the American Diabetes Association's website after August 25. About CCS CCS is the strategic partner addressing America's most pressing healthcare challenges through intelligent chronic care management, tackling the $412 billion annual diabetes burden and chronic conditions affecting over 133 million Americans. At the core of CCS's differentiated model is LivingConnected®, a human-led, digitally enabled clinical solution. PropheSee™ — an AI-powered predictive model that identifies nonadherence risk and delivers personalized interventions — is an integral part of this solution, creating a first-of-its-kind platform to improve adherence, enhance clinical outcomes, and help prevent costly hospitalizations. By combining data-driven insights with three decades of industry relationships, CCS is the smart choice for health plans, providers, employers, and manufacturers who believe that value-based care starts by keeping patients healthy and delivers benefits like lower cost of care, improved HEDIS scores, and alleviating provider burnout. CCS's approach extends clinical reach while supporting over 200,000 people nationwide with home-delivered medical supplies and pharmaceuticals annually. Recognized as a Great Place to Work® and with numerous peer-reviewed publications validating our care management approach, CCS is more than a trusted supplier — we're a partner in transforming chronic care delivery. To learn more about how CCS is addressing today's healthcare challenges, visit or connect with us on LinkedIn.